Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma Appoints Carol Brosgart, MD to Board of Directors

Neutral Impact 2 of 5 leadership Written later

Cocrystal Pharma announced that Carol Brosgart, MD has joined its Board of Directors, effective August 12, 2026. The company said her antiviral drug development experience will support its CDI-988 norovirus program and broader antiviral pipeline.

Key points

  • Board appointment effective August 12, 2026; announced August 17, 2026
  • Dr. Brosgart spent more than a decade at Gilead Sciences, where she worked on Viread and Hepsera
  • Chairman Roger Kornberg said her insights will help advance CDI-988 for norovirus

The filing

CompanyCocrystal Pharma, Inc. (COCP)
Form8-K, current report
Filed with the SECAug 17, 2026, 4:15 PM ET
Accession number0001493152-26-038747

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.